Cambrex Profarmaco Milano Srl, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is TRIAZOLAM, with a corresponding US DMF Number 8704.
Remarkably, this DMF maintains an Active status since its submission on August 06, 1990, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 24, 2016, and payment made on April 29, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II